Tanezumab

Drug Profile

Tanezumab

Alternative Names: PF-04383119; PF-4383119; RI-624; RN-624

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Rinat Neuroscience
  • Developer Eli Lilly; Pfizer
  • Class Monoclonal antibodies; Non-opioid analgesics
  • Mechanism of Action Nerve growth factor inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Back pain; Cancer pain; Musculoskeletal pain; Pain
  • Suspended Diabetic neuropathies
  • No development reported Postherpetic neuralgia

Most Recent Events

  • 01 Jun 2016 Pfizer initiates the phase-III TANGO trial in Back pain in Japan (SC) (NCT02725411)
  • 28 Mar 2016 Pfizer plans the phase III TANGO trial for Back pain in Japan (SC) (NCT02725411)
  • 01 Mar 2016 Phase-III clinical trials in Pain in United Kingdom, Slovakia, Poland, Japan, Germany, Finland, Austria (SC) (NCT02709486; EudraCT201300450821)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top